291 related articles for article (PubMed ID: 30765934)
1. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
[TBL] [Abstract][Full Text] [Related]
2. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
3. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
4. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
5. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.
Andrade P; Rodrigues S; Rodrigues-Pinto E; Gaspar R; Lopes J; Lopes S; Macedo G
GE Port J Gastroenterol; 2017 Jul; 24(4):161-168. PubMed ID: 29255745
[TBL] [Abstract][Full Text] [Related]
9. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
[TBL] [Abstract][Full Text] [Related]
11. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
12. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
[TBL] [Abstract][Full Text] [Related]
14. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
16. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
[TBL] [Abstract][Full Text] [Related]
17. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
[TBL] [Abstract][Full Text] [Related]
18. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
19. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
[TBL] [Abstract][Full Text] [Related]
20. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
